Related Experiment Video
Updated: Apr 2, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Steady progress in the treatment of advanced prostate cancer: a year in review
1Division of Hematology Oncology, Department of Medicine, Medical University of South Carolina Charleston, South Carolina, USA.
Purpose Of Review:
This review is designed to highlight recent research efforts to optimize treatment strategies in men with advanced prostate cancer.
Recent Findings:
In hopes of improving outcomes in men with advanced prostate cancer, recent trials have focused on intensifying therapy earlier in the disease course both in men with biochemical recurrence and those with oligometastatic disease. Further research efforts have looked to refine the use of radiopharmaceuticals, targeted therapy, and combinations of existing agents. Finally, systemic therapies with novel targets may expand options for men with treatment-refractory metastatic castration-resistant disease.
Summary:
Ongoing research focuses on maximizing the benefits of existing therapies while exploring treatments with new mechanisms of action.
Insights
Recent research optimizes advanced prostate cancer treatment by intensifying early therapies and exploring novel agents. This includes refining radiopharmaceuticals, targeted therapies, and new treatments for refractory disease, aiming to improve patient outcomes.
Area of Science:
- Oncology
- Urology
- Medical Research
Background:
- Advanced prostate cancer presents significant treatment challenges.
- Optimizing therapeutic strategies is crucial for improving patient outcomes.
Purpose of the Study:
- To review recent research focused on optimizing treatment strategies for advanced prostate cancer.
- To highlight advancements in therapeutic approaches for various stages of the disease.
Main Methods:
- Literature review of recent clinical trials and research efforts.
- Analysis of studies investigating intensified therapy, radiopharmaceuticals, targeted therapy, and novel systemic agents.
Main Results:
- Trials are intensifying therapy earlier for biochemical recurrence and oligometastatic disease.
- Refinement in the use of radiopharmaceuticals, targeted therapy, and combination therapies is ongoing.
- Novel systemic therapies are being developed for treatment-refractory metastatic castration-resistant prostate cancer.
Conclusions:
- Research aims to maximize benefits from current therapies.
- Exploration of treatments with new mechanisms of action is a key focus for future advancements.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies